<h4>Objectives</h4>The current study evaluated the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and substance use disorders (SUD) in type 2 diabetes and obesity.<h4>Methods</h4>We conducted a retrospective nested case-control study using the All of Us Research Program data. Here, GLP1R is linked to type 2 diabetes mellitus.